LKFT vs NAMS: stock comparison and AI forecast
Lakefront Biotherapeutics Nv (LKFT) and Newamsterdam Pharma Co N.V. (NAMS) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
LKFT Lakefront Biotherapeutics Nv
- Market Cap
- $2.21B
- P/E Ratio
- 5.0x
- Size
- mid-cap
- AI Forecast
NAMS Newamsterdam Pharma Co N.V.
- Market Cap
- $2.26B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- LKFT and NAMS have similar market capitalizations ($2.21B and $2.26B).
- LKFT turns 18.2% of its revenue into net income, against -924.0% for NAMS.
- NAMS carries 0.09 times debt per unit of equity, against 0.05 times for LKFT.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | LKFT | NAMS |
|---|---|---|
| Market Cap | $2.21B | $2.26B |
| P/E Ratio | 5.04x | – |
| P/B Ratio | – | 3.58x |
| EPS | $6.66 | $-1.25 |
| Book Value/Share | – | $5.28 |
| Revenue/Share | $36.68 | $0.19 |
| FCF/Share | $-26.83 | $-1.26 |
Profitability & Margins
| Metric | LKFT | NAMS |
|---|---|---|
| ROE | 12.0% | -32.5% |
| ROA | 11.4% | -29.8% |
| ROIC | -7.7% | -37.0% |
| Gross Margin | 96.3% | – |
| Operating Margin | -11.7% | -1052.8% |
| Net Margin | 18.2% | -924.0% |
| EBT Margin | 4.1% | -918.6% |
| Tax Rate | -9.0% | – |
Financial Health
| Metric | LKFT | NAMS |
|---|---|---|
| Current Ratio | 20.15x | 11.76x |
| Quick Ratio | 20.00x | – |
| D/E Ratio | 0.05x | 0.09x |
| Financial Leverage | 1.05x | 1.09x |
| Working Capital | $3.44B | $615M |
Cash Flow
| Metric | LKFT | NAMS |
|---|---|---|
| Operating Cash Flow | -$1.68B | -$150M |
| Free Cash Flow | -$1.77B | -$151M |
| Capital Spending | -$87M | -$400K |
| FCF/Sales | -73.2% | -680.4% |
| CapEx/Sales | 3.6% | 1.8% |
Operational Efficiency
| Metric | LKFT | NAMS |
|---|---|---|
| Asset Turnover | 0.63x | 0.03x |
| Receivables Turnover | 103.0x | – |
| Inventory Turnover | 3.5x | – |
| Fixed Assets Turnover | 29.6x | 40.0x |
| Days Sales Outstanding | 4 days | – |
| Days Inventory | 105 days | – |
| Payables Period | 488 days | – |
| Cash Conversion Cycle | -379 days | – |
Income Statement
| Metric | LKFT | NAMS |
|---|---|---|
| Total Revenue | $2.42B | $22M |
| Operating Income | -$282M | -$233M |
| Net Income | $440M | -$205M |
| R&D Expense | $1.76B | $158M |
| SG&A Expense | – | $102M |
| Cost of Goods Sold | $89M | – |
Dividend & Shareholder Information
| Metric | LKFT | NAMS |
|---|---|---|
| Shares Outstanding | 66M | 120M |
LKFT vs NAMS: stock comparison and AI forecast
Which is bigger, LKFT or NAMS?
LKFT and NAMS have similar market capitalizations ($2.21B and $2.26B).
Which one does Intratio's AI model rank higher, LKFT or NAMS?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.